|
WO1998011244A2
(en)
|
1996-09-11 |
1998-03-19 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Aav4 vector and uses thereof
|
|
US6759237B1
(en)
*
|
1998-11-05 |
2004-07-06 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
|
|
US6491907B1
(en)
*
|
1998-11-10 |
2002-12-10 |
The University Of North Carolina At Chapel Hill |
Recombinant parvovirus vectors and method of making
|
|
US6627617B1
(en)
|
1999-10-01 |
2003-09-30 |
University Of North Carolina At Chapel Hill |
Temperature-sensitive regulation of viral vector production
|
|
WO2001071018A2
(en)
*
|
2000-03-22 |
2001-09-27 |
Board Of Trustees Of The University Of Arkansas |
Secreting products from skin by adeno-associated virus (aav) gene transfer
|
|
US6855314B1
(en)
*
|
2000-03-22 |
2005-02-15 |
The United States Of America As Represented By The Department Of Health And Human Services |
AAV5 vector for transducing brain cells and lung cells
|
|
CA2406743A1
(en)
|
2000-04-28 |
2001-11-08 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
|
|
WO2002082904A2
(en)
*
|
2001-04-13 |
2002-10-24 |
The Trustees Of The University Of Pennsylvania |
Method of treating or retarding the development of blindness
|
|
DE10120265A1
(de)
*
|
2001-04-25 |
2002-11-14 |
Deutsches Krebsforsch |
AAV-Helferplasmide zur Helfervirus-freien Verpackung und Pseudotypisierung von AAV-Vektoren
|
|
AU2002342653A1
(en)
|
2001-05-14 |
2002-11-25 |
The Gouvernment Of The United States Of America, Represented By The Secretary, Department Of Health |
Modified growth hormone
|
|
US8241622B2
(en)
|
2001-07-13 |
2012-08-14 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences
|
|
HU230406B1
(hu)
|
2001-11-13 |
2016-04-28 |
The Trustees Of The University Of Pennsylvania |
Eljárás adeno-asszociált vírus(AAV)szekvenciák detektálására és/vagy azonosítására és az azzal azonosított új szekvenciák izolálására
|
|
DK2573170T3
(en)
|
2001-12-17 |
2018-04-09 |
Univ Pennsylvania |
Sequences of adeno-associated virus (AAV) serotype 9, vectors containing them, and their use
|
|
AU2002360291A1
(en)
|
2001-12-17 |
2003-06-30 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus (aav) serotype 8 sequences
|
|
US7419817B2
(en)
|
2002-05-17 |
2008-09-02 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. |
Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
|
|
US8927269B2
(en)
|
2003-05-19 |
2015-01-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Avian adenoassociated virus and uses thereof
|
|
US8529885B2
(en)
|
2003-09-01 |
2013-09-10 |
Academisch Medisch Centrum |
AAV vectors for in vivo gene therapy of rheumatoid arthritis
|
|
PL1664315T3
(pl)
*
|
2003-09-01 |
2012-09-28 |
Acad Medisch Ct |
Wektory aav do terapii genowej in vivo reumatoidalnego zapalenia stawów
|
|
HUE054805T2
(hu)
|
2003-09-30 |
2021-09-28 |
Univ Pennsylvania |
Adeno-asszociált vírus (AAV) kládok, szekvenciák, az azokat tartalmazó vektorok és alkalmazásaik
|
|
US8137960B2
(en)
|
2003-12-04 |
2012-03-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
Bovine adeno-associated viral (BAAV) vector and uses thereof
|
|
DK1697399T3
(en)
|
2003-12-12 |
2017-03-06 |
Government Of The United States Of America As Repr By The Secr Of The Dept Of Health And Human Servi |
Human cytotoxic t lymphocyte epitope and its agonist epitope from the non-variable number of muc-1 tandem repeat sequences
|
|
WO2006029196A1
(en)
*
|
2004-09-08 |
2006-03-16 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of H Ealth |
Transcytosis of adeno-associated viruses
|
|
ES2385837T3
(es)
|
2004-12-15 |
2012-08-01 |
The University Of North Carolina At Chapel Hill |
Vectores quiméricos
|
|
ES2525067T3
(es)
|
2005-04-07 |
2014-12-17 |
The Trustees Of The University Of Pennsylvania |
Método de incremento de la función de un vector de AAV
|
|
US8283151B2
(en)
|
2005-04-29 |
2012-10-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
|
|
WO2007109583A2
(en)
|
2006-03-17 |
2007-09-27 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject
|
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
WO2010093784A2
(en)
|
2009-02-11 |
2010-08-19 |
The University Of North Carolina At Chapel Hill |
Modified virus vectors and methods of making and using the same
|
|
CN102448501A
(zh)
|
2009-03-27 |
2012-05-09 |
西马生物医学计划公司 |
治疗肝硬化和肝纤维化的方法和组合物
|
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
|
RU2012123145A
(ru)
|
2009-11-05 |
2013-12-10 |
Проекто Де Биомедисина Сима, С.Л. |
Генный конструкт (варианты), вектор и рекомбинантный вирусный геном на его основе, вирион, их фармацевтическая композиция, способ in vitro экспрессии полинуклеотида в клетке печеночной природы, лекарственное средство, способ лечения заболевания печени (варианты), индуцируемый двунаправленный оператор-промотор
|
|
US9169494B2
(en)
|
2010-01-12 |
2015-10-27 |
The University Of North Carolina At Chapel Hill |
Restrictive inverted terminal repeats for viral vectors
|
|
CA3050894C
(en)
|
2010-04-23 |
2022-10-18 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
CA2833908C
(en)
|
2010-04-23 |
2021-02-09 |
University Of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
|
CN102918152B
(zh)
*
|
2010-04-23 |
2016-04-13 |
佛罗里达大学研究基金公司 |
用于治疗莱伯氏先天性黑蒙-1（lca1）的raav-鸟苷酸环化酶组合物及方法
|
|
CA2833912C
(en)
|
2010-04-23 |
2021-09-21 |
University Of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
|
WO2012007458A1
(en)
|
2010-07-12 |
2012-01-19 |
Universidad Autónoma De Barcelona |
Gene therapy composition for use in diabetes treatment
|
|
WO2012145624A2
(en)
|
2011-04-21 |
2012-10-26 |
University Of Massachusetts |
Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
|
RS62795B1
(sr)
|
2011-04-22 |
2022-02-28 |
Univ California |
Adeno-povezani virioni virusa sa varijantama kapsida i postupci za njihovu primenu
|
|
JP6562632B2
(ja)
*
|
2012-02-14 |
2019-08-21 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
心血管疾患および他の状態のためのパラクリン遺伝子の全身送達および制御された発現
|
|
EP2692868A1
(de)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adenoassoziierte virale (AAV) Vektoren für die Transduktion von Fettgewebe
|
|
US9636370B2
(en)
|
2012-09-28 |
2017-05-02 |
The University Of North Carolina At Chapel Hill |
AAV vectors targeted to oligodendrocytes
|
|
WO2014059173A2
(en)
|
2012-10-10 |
2014-04-17 |
Sangamo Biosciences, Inc. |
T cell modifying compounds and uses thereof
|
|
EP3517612A1
(de)
|
2013-03-15 |
2019-07-31 |
The University of North Carolina At Chapel Hill |
Synthetische adenoassoziierte virusinvertierte endwiederholungssequenzen
|
|
EP3567112A1
(de)
|
2013-06-13 |
2019-11-13 |
Translate Bio, Inc. |
Virenproduktion auf messenger-rna-basis
|
|
CN116004721A
(zh)
*
|
2013-07-12 |
2023-04-25 |
费城儿童医院 |
Aav载体和用于抗aav（腺相关病毒）中和抗体的检测
|
|
US20160354489A1
(en)
|
2013-09-26 |
2016-12-08 |
Universitat Autònome de Barcelona |
Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease
|
|
EP3795697B1
(de)
|
2014-02-04 |
2024-09-18 |
Jumpcode Genomics, Inc. |
Genomfraktionierung
|
|
GB201403684D0
(en)
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
|
WO2015127128A2
(en)
|
2014-02-19 |
2015-08-27 |
University Of Massachusetts |
Recombinant aavs having useful transcytosis properties
|
|
US9890365B2
(en)
|
2014-03-09 |
2018-02-13 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency
|
|
ES2856403T3
(es)
|
2014-03-18 |
2021-09-27 |
Univ Massachusetts |
Composiciones a base de rAAV y procedimientos para el tratamiento de la esclerosis lateral amiotrofica
|
|
US10975391B2
(en)
|
2014-04-25 |
2021-04-13 |
University Of Massachusetts |
Recombinant AAV vectors useful for reducing immunity against transgene products
|
|
US10689653B2
(en)
|
2014-06-03 |
2020-06-23 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
WO2015191508A1
(en)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
US9458464B2
(en)
|
2014-06-23 |
2016-10-04 |
The Johns Hopkins University |
Treatment of neuropathic pain
|
|
WO2016041588A1
(en)
|
2014-09-16 |
2016-03-24 |
Universitat Autònoma De Barcelona |
Adeno-associated viral vectors for the gene therapy of metabolic diseases
|
|
WO2016054554A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Heterologous targeting peptide grafted aavs
|
|
EP3795580A1
(de)
|
2014-10-03 |
2021-03-24 |
University of Massachusetts |
Hocheffiziente bibliotheksidentifizierte aav-vektoren
|
|
WO2016065001A1
(en)
*
|
2014-10-21 |
2016-04-28 |
University Of Massachusetts |
Recombinant aav variants and uses thereof
|
|
JP6401871B2
(ja)
|
2014-11-05 |
2018-10-10 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
パーキンソン病の治療のためのａａｄｃポリヌクレオチド
|
|
SG11201703419UA
(en)
|
2014-11-14 |
2017-05-30 |
Voyager Therapeutics Inc |
Modulatory polynucleotides
|
|
HK1244299A1
(zh)
|
2014-11-14 |
2018-08-03 |
Voyager Therapeutics, Inc. |
治療肌萎縮側索硬化(als)的組合物和方法
|
|
EP4344741A3
(de)
|
2014-11-21 |
2024-08-28 |
The University of North Carolina at Chapel Hill |
Auf das zentrale nervensystem gerichtete aav-vektoren
|
|
US11697825B2
(en)
|
2014-12-12 |
2023-07-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scAAV
|
|
EP3242945B1
(de)
|
2015-01-07 |
2021-09-01 |
Universitat Autònoma de Barcelona |
Einzelvektor-genkonstrukt mit insulin- und glucokinasegenen
|
|
US10907176B2
(en)
|
2015-01-14 |
2021-02-02 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for targeted gene transfer
|
|
US10308705B2
(en)
|
2015-02-06 |
2019-06-04 |
The University Of North Carolina At Chapel Hill |
Optimized human clotting factor VIII gene expression cassettes and their use
|
|
US10584321B2
(en)
|
2015-02-13 |
2020-03-10 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
US10968536B2
(en)
|
2015-02-25 |
2021-04-06 |
Jumpcode Genomics, Inc. |
Methods and compositions for sequencing
|
|
US10081659B2
(en)
|
2015-04-06 |
2018-09-25 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Adeno-associated vectors for enhanced transduction and reduced immunogenicity
|
|
WO2016172008A1
(en)
|
2015-04-24 |
2016-10-27 |
University Of Massachusetts |
Modified aav constructions and uses thereof
|
|
WO2017027866A1
(en)
*
|
2015-08-13 |
2017-02-16 |
University Of Florida Research Foundation, Inc. |
Aav6 vectors for immunotherapy
|
|
IL314171A
(en)
|
2015-09-28 |
2024-09-01 |
Univ Florida |
Methods and compositions for antibody-evading virus vectors
|
|
US20190038659A1
(en)
|
2015-09-29 |
2019-02-07 |
The Usa, As Represented By The Secretary, Department Of Health And Human Services |
Methods of treating and preventing amyotrophic lateral sclerosis
|
|
EP3364996B1
(de)
|
2015-10-22 |
2021-08-25 |
University of Massachusetts |
Gegen die prostata gerichtete adeno-assoziierte virusserotypvektoren
|
|
WO2017070525A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
|
SG10201912763QA
(en)
|
2015-11-05 |
2020-02-27 |
Bamboo Therapeutics Inc |
Modified friedreich ataxia genes and vectors for gene therapy
|
|
WO2017096162A1
(en)
|
2015-12-02 |
2017-06-08 |
Voyager Therapeutics, Inc. |
Assays for the detection of aav neutralizing antibodies
|
|
CN116478254A
(zh)
|
2015-12-14 |
2023-07-25 |
北卡罗来纳大学教堂山分校 |
增强细小病毒载体递送的修饰衣壳蛋白
|
|
CN116948988A
(zh)
*
|
2016-01-29 |
2023-10-27 |
西里昂生物技术有限责任公司 |
基于aav的条件表达系统
|
|
US11826433B2
(en)
|
2016-02-02 |
2023-11-28 |
University Of Massachusetts |
Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system
|
|
EP3411484B1
(de)
|
2016-02-05 |
2023-10-04 |
Emory University |
Injektion von einzelsträngigem oder selbstkomplementärem adeno-assoziiertem virus 9 in den liquor
|
|
US11702672B2
(en)
|
2016-02-08 |
2023-07-18 |
University Of Iowa Research Foundation |
Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
|
|
US11339427B2
(en)
|
2016-02-12 |
2022-05-24 |
Jumpcode Genomics, Inc. |
Method for target specific RNA transcription of DNA sequences
|
|
US11060088B2
(en)
|
2016-02-12 |
2021-07-13 |
University Of Massachusetts |
Anti-angiogenic miRNA therapeutics for inhibiting corneal neovascularization
|
|
HK1255692A1
(zh)
|
2016-02-22 |
2019-08-23 |
北卡罗来纳大学教堂山分校 |
治療mps i-相關失明的aav-idua載體
|
|
EP3426787A1
(de)
|
2016-03-07 |
2019-01-16 |
University of Iowa Research Foundation |
Aav-vermittelte expression unter verwendung eines synthetischer promoters und verstärkers
|
|
WO2017176929A1
(en)
|
2016-04-05 |
2017-10-12 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
|
WO2017181105A1
(en)
|
2016-04-15 |
2017-10-19 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
EP3449250B1
(de)
|
2016-04-28 |
2020-11-04 |
Indiana University Research & Technology Corporation |
Verfahren und zusammensetzungen zur auflösung von komponenten einer viruspräparation
|
|
US11326182B2
(en)
|
2016-04-29 |
2022-05-10 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
EP3448437B1
(de)
|
2016-04-29 |
2021-12-29 |
Adverum Biotechnologies, Inc. |
Evasion von neutralisierenden antikörpern durch ein rekombinantes adeno-assoziiertes virus
|
|
EP3448987A4
(de)
|
2016-04-29 |
2020-05-27 |
Voyager Therapeutics, Inc. |
Zusammensetzungen zur behandlung einer erkrankung
|
|
CR20180589A
(es)
|
2016-05-13 |
2019-02-27 |
4D Molecular Therapeutics Inc |
Cápsulas variantes de virus adenoasociados y métodos de uso de estas
|
|
KR102427379B1
(ko)
|
2016-05-18 |
2022-08-02 |
보이저 테라퓨틱스, 인크. |
헌팅톤 질환을 치료하기 위한 조성물 및 방법
|
|
JP7066635B2
(ja)
|
2016-05-18 |
2022-05-13 |
ボイジャー セラピューティクス インコーポレイテッド |
調節性ポリヌクレオチド
|
|
WO2017205739A1
(en)
|
2016-05-26 |
2017-11-30 |
University Of Iowa Research Foundation |
cis AND trans REQUIREMENTS FOR TERMINAL RESOLUTION OF HUMAN BOCAVIRUS 1
|
|
RU2764919C2
(ru)
|
2016-06-13 |
2022-01-24 |
Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл |
Оптимизированные гены и экспрессионные кассеты cln1, и их применение
|
|
WO2017218852A1
(en)
|
2016-06-15 |
2017-12-21 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
CA2971303A1
(en)
|
2016-06-21 |
2017-12-21 |
Bamboo Therapeutics, Inc. |
Optimized mini-dystrophin genes and expression cassettes and their use
|
|
CN110167958A
(zh)
|
2016-07-26 |
2019-08-23 |
北卡罗来纳大学教堂山分校 |
载体介导的眼睛免疫耐受性
|
|
JP2019531787A
(ja)
|
2016-08-30 |
2019-11-07 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
生物医学的ターゲティング及びデリバリーの方法並びにそれを実行するための装置及びシステム
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
KR20190075964A
(ko)
|
2016-10-13 |
2019-07-01 |
유니버시티 오브 매사추세츠 |
Aav 캡시드 설계
|
|
US11192925B2
(en)
|
2016-10-19 |
2021-12-07 |
Adverum Biotechnologies, Inc. |
Modified AAV capsids and uses thereof
|
|
EP3535396A1
(de)
|
2016-11-01 |
2019-09-11 |
Novartis AG |
Verfahren und zusammensetzungen zur verbesserung der genbearbeitung
|
|
WO2018132747A1
(en)
|
2017-01-13 |
2018-07-19 |
University Of Iowa Research Foundation |
Bocaparvovirus small noncoding rna and uses thereof
|
|
EP3570895A1
(de)
|
2017-01-17 |
2019-11-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur expression eines bestimmten polynukleotids in den zapfen-fotorezeptoren
|
|
CN110462037A
(zh)
*
|
2017-01-30 |
2019-11-15 |
学校法人日本医科大学 |
腺相关病毒(aav)衣壳蛋白的突变体
|
|
CN117801075A
(zh)
|
2017-03-15 |
2024-04-02 |
北卡罗来纳-查佩尔山大学 |
多倍体腺相关病毒载体及其制备和使用方法
|
|
EP3388520A1
(de)
|
2017-04-11 |
2018-10-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzung zur reduzierung der expression von nkcc1 in einer darauf angewiesenen person
|
|
SG11201909868YA
(en)
|
2017-05-05 |
2019-11-28 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease
|
|
EP3618839A4
(de)
|
2017-05-05 |
2021-06-09 |
Voyager Therapeutics, Inc. |
Zusammensetzungen und verfahren zur behandlung von amyotropher lateralsklerose (als)
|
|
WO2018208972A1
(en)
|
2017-05-09 |
2018-11-15 |
University Of Massachusetts |
Methods of treating amyotrophic lateral sclerosis (als)
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
CN111132626B
(zh)
|
2017-07-17 |
2024-01-30 |
沃雅戈治疗公司 |
轨迹阵列引导系统
|
|
AU2018307877A1
(en)
|
2017-07-27 |
2020-01-02 |
Novartis Ag |
Sheddase resistant TREM2 variants
|
|
EP3808849A1
(de)
|
2017-08-03 |
2021-04-21 |
Voyager Therapeutics, Inc. |
Zusammensetzungen und verfahren zur aav-freisetzung
|
|
US20190085358A1
(en)
*
|
2017-08-25 |
2019-03-21 |
Ovid Therapeutics Inc. |
Recombinant adeno-associated vectors
|
|
EP3684423B1
(de)
|
2017-09-20 |
2023-03-29 |
4D Molecular Therapeutics Inc. |
Variante kapside mit adeno-assoziiertem virus und verfahren zur verwendung davon
|
|
US11668719B2
(en)
|
2017-09-20 |
2023-06-06 |
The Trustees Of Indiana University |
Methods for resolving lipoproteins with mass spectrometry
|
|
JP7397488B2
(ja)
|
2017-09-22 |
2023-12-13 |
ユニバーシティ オブ マサチューセッツ |
Ｓｏｄ１二重発現ベクターおよびその使用
|
|
MX2020003042A
(es)
|
2017-09-29 |
2020-11-18 |
Voyager Therapeutics Inc |
Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
|
|
US20200237799A1
(en)
|
2017-10-16 |
2020-07-30 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
US11434502B2
(en)
|
2017-10-16 |
2022-09-06 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (ALS)
|
|
KR102763312B1
(ko)
|
2017-10-20 |
2025-02-07 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
치료적으로 유효한 양의 재조합 aav9- 유도 벡터의 망막하 전달을 포함하는 대상체의 원추 광수용체 내 관심의 폴리뉴클레오티드를 발현하는 방법
|
|
US11491241B2
(en)
|
2017-11-07 |
2022-11-08 |
The University Of North Carolina At Chapel Hill |
Optimized AGA genes and expression cassettes and their use
|
|
CA3083472A1
(en)
|
2017-11-27 |
2019-05-31 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and use for inhibiting angiogenesis
|
|
WO2019140233A1
(en)
|
2018-01-12 |
2019-07-18 |
The Trustees Of Indiana University |
Electrostatic linear ion trap design for charge detection mass spectrometry
|
|
CN111601620A
(zh)
|
2018-01-17 |
2020-08-28 |
阿瑞纳斯治疗公司 |
用于21-羟化酶缺乏症的腺相关病毒基因疗法
|
|
AU2019225992A1
(en)
|
2018-02-21 |
2020-08-20 |
Alcyone Therapeutics, Inc. |
Fluid delivery systems and methods
|
|
BR112020016699A2
(pt)
|
2018-02-28 |
2020-12-15 |
The University Of North Carolina At Chapel Hill |
Métodos e composições para vetores de vírus de evasão de anticorpos
|
|
CA3094311A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Antibody-evading virus vectors
|
|
WO2019195423A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Virus vectors for targeting ophthalmic tissues
|
|
AU2019247746B2
(en)
|
2018-04-03 |
2024-08-15 |
Ginkgo Bioworks, Inc. |
Antibody-evading virus vectors
|
|
WO2019217294A1
(en)
|
2018-05-06 |
2019-11-14 |
Emendobio Inc. |
Differential knockout of an allele of a heterozygous elane gene
|
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
|
AU2019268330A1
(en)
|
2018-05-15 |
2020-11-26 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of Parkinson's disease
|
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
AU2019281714B2
(en)
|
2018-06-04 |
2024-05-02 |
The Trustees Of Indiana University |
Charge detection mass spectrometry with real time analysis and signal optimization
|
|
US11227759B2
(en)
|
2018-06-04 |
2022-01-18 |
The Trustees Of Indiana University |
Ion trap array for high throughput charge detection mass spectrometry
|
|
CA3100840A1
(en)
|
2018-06-04 |
2019-12-12 |
The Trustees Of Indiana University |
Apparatus and method for capturing ions in an electrostatic linear ion trap
|
|
WO2019236143A1
(en)
|
2018-06-04 |
2019-12-12 |
The Trustees Of Indiana University |
Apparatus and method for calibrating or resetting a charge detector
|
|
WO2019236139A1
(en)
|
2018-06-04 |
2019-12-12 |
The Trustees Of Indiana University |
Interface for transporting ions from an atmospheric pressure environment to a low pressure environment
|
|
EP3802829A4
(de)
|
2018-06-08 |
2022-10-19 |
University of Massachusetts |
Antisense-oligonukleotide zur wiederherstellung der dysferlinproteinexpression bei zellen von patienten mit dysferlinopathie
|
|
EP3807297A4
(de)
|
2018-06-12 |
2022-03-23 |
The University of North Carolina at Chapel Hill |
Synthetische lebertropische adeno-assoziierte viruskapside und deren verwendungen
|
|
US12060567B2
(en)
|
2018-06-13 |
2024-08-13 |
Voyager Therapeutics, Inc. |
Engineered untranslated regions (UTR) for AAV production
|
|
US12275948B2
(en)
|
2018-06-28 |
2025-04-15 |
The University Of North Carolina At Chapel Hill |
Optimized CLN5 genes and expression cassettes and their use
|
|
WO2020023612A1
(en)
|
2018-07-24 |
2020-01-30 |
Voyager Therapeutics, Inc. |
Systems and methods for producing gene therapy formulations
|
|
IL280300B2
(en)
|
2018-08-10 |
2025-06-01 |
Univ North Carolina Chapel Hill |
Optimization of CLN7 genes and expression cassettes and their use
|
|
CN112867529B
(zh)
|
2018-08-27 |
2023-06-02 |
亚克安娜医疗有限公司 |
流体递送系统和方法
|
|
WO2020069029A1
(en)
|
2018-09-26 |
2020-04-02 |
Emendobio Inc. |
Novel crispr nucleases
|
|
SG11202103151RA
(en)
|
2018-09-28 |
2021-04-29 |
Voyager Therapeutics Inc |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
TW202035689A
(zh)
|
2018-10-04 |
2020-10-01 |
美商航海家醫療公司 |
測量病毒載體粒子的效價及強度之方法
|
|
US20210348194A1
(en)
|
2018-10-05 |
2021-11-11 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding aav production proteins
|
|
TW202028468A
(zh)
|
2018-10-15 |
2020-08-01 |
美商航海家醫療公司 |
用於桿狀病毒/Sf9系統中rAAV之大規模生產的表現載體
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
US12270057B2
(en)
|
2018-11-05 |
2025-04-08 |
The University Of North Carolina At Chapel Hill |
Optimized FIG4 genes and expression cassettes and their use
|
|
CA3118267A1
(en)
|
2018-11-20 |
2020-05-28 |
The Trustees Of Indiana University |
Orbitrap for single particle mass spectrometry
|
|
WO2020117292A1
(en)
|
2018-12-03 |
2020-06-11 |
The Trustees Of Indiana University |
Apparatus and method for simultaneously analyzing multiple ions with an electrostatic linear ion trap
|
|
US12359181B2
(en)
|
2018-12-21 |
2025-07-15 |
The University Of North Carolina At Chapel Hill |
Optimized GALC genes and expression cassettes and their use
|
|
US20220098621A1
(en)
|
2019-02-05 |
2022-03-31 |
Emendobio Inc. |
Crispr compositions and methods for promoting gene editing of ribosomal protein s19 (rps19) gene
|
|
US20220154157A1
(en)
|
2019-02-06 |
2022-05-19 |
Emendobio Inc. |
New engineered high fidelity cas9
|
|
JP2022520875A
(ja)
|
2019-02-25 |
2022-04-01 |
ノバルティス アーゲー |
Ｂｉｅｔｔｉクリスタリン網膜症を治療するための組成物及び方法
|
|
BR112021016501A2
(pt)
|
2019-02-25 |
2021-10-26 |
Novartis Ag |
Composições e métodos para tratar distrofia cristalina de bietti
|
|
WO2020191300A1
(en)
|
2019-03-21 |
2020-09-24 |
Stridebio, Inc. |
Recombinant adeno-associated virus vectors
|
|
AU2020253435A1
(en)
|
2019-04-01 |
2021-11-18 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
|
US20220280655A1
(en)
|
2019-04-23 |
2022-09-08 |
Institut National de la Santé et de la Recherche Médicale |
New Adeno-Associated Virus (AAV) Variants and Uses Thereof for Gene Therapy
|
|
CA3137876A1
(en)
|
2019-04-23 |
2020-10-29 |
The Trustees Of Indiana University |
Identification of sample subspecies based on particle charge behavior under structural change-inducing sample conditions
|
|
WO2020219988A2
(en)
|
2019-04-26 |
2020-10-29 |
Sangamo Therapeutics, Inc. |
Engineering aav
|
|
AR118928A1
(es)
*
|
2019-05-14 |
2021-11-10 |
Biomarin Pharm Inc |
Métodos de redosificación de vectores de terapia génica
|
|
PE20212357A1
(es)
*
|
2019-05-24 |
2021-12-17 |
Regeneron Pharma |
Particulas virales modificadas y usos de estas
|
|
US20230241248A1
(en)
|
2019-06-27 |
2023-08-03 |
Pfizer Inc. |
Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
|
|
US10557149B1
(en)
|
2019-07-15 |
2020-02-11 |
Vigene Biosciences, Inc. |
Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
|
|
US10653731B1
(en)
|
2019-07-15 |
2020-05-19 |
Vigene Biosciences Inc. |
Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
|
|
US10801042B1
(en)
|
2019-07-15 |
2020-10-13 |
Vigene Biosciences, Inc. |
Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus
|
|
WO2021053559A1
(en)
|
2019-09-18 |
2021-03-25 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
EP4035200A4
(de)
|
2019-09-25 |
2023-12-27 |
The Trustees of Indiana University |
Gerät und verfahren zur ladungsdetektionsmassenspektrometrie im gepulsten modus
|
|
GB201913974D0
(en)
|
2019-09-27 |
2019-11-13 |
King S College London |
Vector
|
|
US11905523B2
(en)
|
2019-10-17 |
2024-02-20 |
Ginkgo Bioworks, Inc. |
Adeno-associated viral vectors for treatment of Niemann-Pick Disease type-C
|
|
JP7690209B2
(ja)
|
2019-12-18 |
2025-06-10 |
ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー |
電荷測定装置を有する質量分析計
|
|
US12183566B2
(en)
|
2020-02-03 |
2024-12-31 |
The Trustees Of Indiana University |
Time-domain analysis of signals for charge detection mass spectrometry
|
|
US20230136699A1
(en)
|
2020-02-28 |
2023-05-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Gene therapy for maple syrup urine disease
|
|
EP4121168A1
(de)
|
2020-03-20 |
2023-01-25 |
University of Florida Research Foundation, Inc. |
Gentherapie für das schabyne-syndrom
|
|
WO2021194915A1
(en)
|
2020-03-23 |
2021-09-30 |
The University Of North Carolina At Chapel Hill |
Aav-naglu vectors for treatment of mucopolysaccharidosis iiib
|
|
KR20220167324A
(ko)
|
2020-04-10 |
2022-12-20 |
솔라 바이오사이언시즈 엘엘씨 |
단백질 응집 장애의 치료를 위한 조성물 및 방법
|
|
JP7393565B2
(ja)
|
2020-04-27 |
2023-12-06 |
４ディー モレキュラー セラピューティクス インコーポレイテッド |
肺送達のためのアデノ随伴バリアント、製剤および方法
|
|
KR20230025659A
(ko)
|
2020-04-28 |
2023-02-22 |
솔라 바이오사이언시즈 엘엘씨 |
Tdp-43 단백질병증의 치료를 위한 조성물 및 방법
|
|
CN115916986A
(zh)
|
2020-05-05 |
2023-04-04 |
北卡罗来纳大学查佩尔希尔分校 |
修饰的腺相关病毒5衣壳及其用途
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
CA3183251A1
(en)
|
2020-06-05 |
2021-12-09 |
Sola Biosciences Llc |
Compositions and methods for the treatment of synucleinopathies
|
|
US20230285595A1
(en)
|
2020-07-23 |
2023-09-14 |
The University Of North Carolina At Chapel Hill |
Optimized slc13a5 genes and expression cassettes and their use
|
|
IL300717A
(en)
|
2020-08-19 |
2023-04-01 |
Sarepta Therapeutics Inc |
ADENO-related virus vectors for the treatment of RETT syndrome
|
|
JP2023548816A
(ja)
|
2020-11-03 |
2023-11-21 |
ファイザー・インク |
陰イオン交換クロマトグラフィーによるａａｖベクターの精製方法
|
|
WO2022130172A1
(en)
|
2020-12-15 |
2022-06-23 |
Pfizer Inc. |
Hilic uplc-ms method for separating and analyzing intact adeno-associated virus capsid proteins
|
|
JP2024503234A
(ja)
|
2020-12-23 |
2024-01-25 |
ファイザー・インク |
親和性クロマトグラフィーによるａａｖベクターの精製方法
|
|
TW202242124A
(zh)
|
2021-01-14 |
2022-11-01 |
美商史崔德生物公司 |
靶向ｔ細胞之ａａｖ載體
|
|
WO2022208342A1
(en)
|
2021-04-01 |
2022-10-06 |
Pfizer Inc. |
Pharmaceutical compositions containing adeno-associated viral vector
|
|
US20240189447A1
(en)
|
2021-04-16 |
2024-06-13 |
Asklepios Biopharmaceutical, Inc. |
Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
|
|
JP2024515902A
(ja)
|
2021-04-26 |
2024-04-10 |
アレクシオン ファーマ インターナショナル オペレーションズ リミテッド |
組織向性が改善されたアデノ随伴ウイルスベクターカプシド
|
|
JP2024519888A
(ja)
|
2021-05-28 |
2024-05-21 |
上海瑞宏迪医薬有限公司 |
カプシド変異を有する組換えアデノ随伴ウイルス及びその応用
|
|
US20220396798A1
(en)
*
|
2021-06-12 |
2022-12-15 |
Shi-Lung Lin |
Novel mrna composition and production method for use in anti-viral and anti-cancer vaccines
|
|
JP2023002483A
(ja)
|
2021-06-22 |
2023-01-10 |
ファイザー・インク |
昆虫細胞におけるアデノ随伴ウイルスベクターの産生
|
|
CA3224488A1
(en)
|
2021-07-08 |
2023-01-12 |
Tenaya Therapeutics, Inc. |
Optimized expression cassettes for gene therapy
|
|
AU2022327583A1
(en)
|
2021-08-11 |
2024-02-22 |
King's College London |
Compositions and methods for improved treatment of disorders affecting the central nervous system
|
|
US20240400626A1
(en)
|
2021-10-08 |
2024-12-05 |
Sola Biosciences Llc |
Compositions and methods for the treatment of p53-mediated cancers
|
|
US20250042958A1
(en)
|
2021-10-08 |
2025-02-06 |
Sola Biosciences Llc |
Compositions and methods for the treatment of proteopathies
|
|
AU2022368907A1
(en)
|
2021-10-20 |
2024-05-02 |
University Of Copenhagen |
Rejuvenation treatment of age-related white matter loss
|
|
JP2024542015A
(ja)
|
2021-11-02 |
2024-11-13 |
ユニバーシティ オブ ロチェスター |
脳内でのｔｃｆ７ｌ２媒介性髄鞘再生
|
|
MX2024005314A
(es)
|
2021-11-04 |
2024-05-17 |
Regeneron Pharma |
Particulas virales redirigidas a musculo esqueletico.
|
|
WO2023114816A1
(en)
|
2021-12-14 |
2023-06-22 |
Neurogene, Inc. |
Recombinant optimized galc constructs and methods for treating galc-associated disorders
|
|
GB202201242D0
(en)
|
2022-01-31 |
2022-03-16 |
Univ Edinburgh |
Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
|
|
WO2023150687A1
(en)
|
2022-02-04 |
2023-08-10 |
Ginkgo Bioworks, Inc. |
Recombinant adeno-associated virus vectors, and methods of use thereof
|
|
TW202404993A
(zh)
|
2022-04-11 |
2024-02-01 |
美商特納亞治療股份有限公司 |
具經工程化蛋白殼之腺相關病毒
|
|
GB202206336D0
(en)
|
2022-04-29 |
2022-06-15 |
Univ Edinburgh |
Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
|
|
JP2025517628A
(ja)
|
2022-05-06 |
2025-06-10 |
ノバルティス アーゲー |
新規の組換えａａｖ ｖｐ２融合ポリペプチド
|
|
AU2023269134A1
(en)
|
2022-05-09 |
2024-12-12 |
Regeneron Pharmaceuticals, Inc. |
Vectors and methods for in vivo antibody production
|
|
WO2024003687A1
(en)
|
2022-06-28 |
2024-01-04 |
Pfizer Inc. |
Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
|
|
KR20250058783A
(ko)
|
2022-07-29 |
2025-04-30 |
리제너론 파마슈티칼스 인코포레이티드 |
트랜스페린 수용체 1로 재표적화된 바이러스 입자
|
|
WO2024038365A1
(en)
|
2022-08-16 |
2024-02-22 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
|
WO2024107765A2
(en)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
|
WO2024124019A2
(en)
|
2022-12-07 |
2024-06-13 |
Ginkgo Bioworks, Inc. |
Aav vectors targeting hematopoietic stem cells
|
|
AU2023395983A1
(en)
|
2022-12-16 |
2025-06-05 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind to aav particles and uses
|
|
WO2024147114A1
(en)
|
2023-01-06 |
2024-07-11 |
Bloomsbury Genetic Therapies Limited |
Compositions and methods for treating parkinson's disease
|
|
WO2024163747A2
(en)
|
2023-02-02 |
2024-08-08 |
University Of Rochester |
Competitive replacement of glial cells
|
|
WO2024173248A1
(en)
|
2023-02-13 |
2024-08-22 |
Regeneron Pharmaceuticals, Inc. |
Treatment of muscle related disorders with anti-human cacng1 antibodies
|
|
WO2024215655A1
(en)
|
2023-04-10 |
2024-10-17 |
Tenaya Therapeutics, Inc. |
Cardioprotective bag3 therapies
|
|
WO2024215653A1
(en)
|
2023-04-10 |
2024-10-17 |
Tenaya Therapeutics, Inc. |
Guide rnas, vectors, and virions for targeting mutations in the pln gene
|
|
WO2024229105A1
(en)
|
2023-05-02 |
2024-11-07 |
Regeneron Pharmaceuticals, Inc. |
Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells
|
|
WO2025042428A1
(en)
|
2023-08-18 |
2025-02-27 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules and uses thereof
|
|
WO2025082618A1
(en)
|
2023-10-20 |
2025-04-24 |
Fuse Vectors Aps |
In vitro parvovirus capsid manufacturing
|
|
WO2025090427A1
(en)
|
2023-10-23 |
2025-05-01 |
University Of Rochester |
Glial-targeted relief of hyperexcitability in neurodegenerative diseases
|
|
WO2025090858A1
(en)
|
2023-10-27 |
2025-05-01 |
Biogen Ma Inc. |
Methods for identifying aav capsid variants with desired characteristics
|